Management of Salivary Gland Malignancy: ASCO Guideline
J.L. Geiger(Cleveland Clinic), Patrick K. Ha(University of California, San Francisco), Marnie Kaufman, Lisa Licitra(University of Milan), Paul Swiecicki(University of Michigan), Raja R. Seethala(University of Pittsburgh), Eric Lamarre(Cleveland Clinic), Jimmy J. Caudell(Moffitt Cancer Center), Beth M. Beadle(Stanford University), Michael G. Moore(Indiana University School of Medicine), Nofisat Ismaila(American Society of Clinical Oncology), Anna Roshal(Indiana University Health), Cristina P. Rodriguez(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Daniel G. Deschler(Ludwig-Maximilians-Universität München), Harold Lau(University of Calgary), Nicole G. Chau(University of British Columbia), Christine M. Glastonbury(University of California, San Francisco)
Cited by 401
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer
|Cell|2017|2.6k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma
|JAMA Oncology|2016|1.4k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k